Free Trial

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos logo
$150.88 +7.14 (+4.97%)
(As of 12/20/2024 05:40 PM ET)

Glaukos - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
1
Buy
11

Based on 13 Wall Street analysts who have issued ratings for Glaukos in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 1 has given a sell rating, 1 has given a hold rating, 10 have given a buy rating, and 1 has given a strong buy rating for GKOS.

Consensus Price Target

$145.92
-3.29% Downside
According to the 13 analysts' twelve-month price targets for Glaukos, the average price target is $145.92. The highest price target for GKOS is $185.00, while the lowest price target for GKOS is $100.00. The average price target represents a forecasted downside of -3.29% from the current price of $150.88.
Get the Latest News and Ratings for GKOS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Glaukos and its competitors.

Sign Up

GKOS Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
10 Buy rating(s)
8 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
Hold
1 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$145.92$134.55$129.82$85.55
Forecasted Upside-3.29% Downside-4.54% Downside1.60% Upside3.93% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

GKOS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GKOS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Glaukos Stock vs. The Competition

TypeGlaukosMedical CompaniesS&P 500
Consensus Rating Score
2.85
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-3.29% Downside25,828.56% Upside14.54% Upside
News Sentiment Rating
Positive News

See Recent GKOS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/18/2024Truist Financial
2 of 5 stars
R. Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$152.00 ➝ $185.00+26.89%
12/11/2024Wells Fargo & Company
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$145.00 ➝ $153.00+6.02%
12/11/2024Citigroup
3 of 5 stars
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$132.00 ➝ $162.00+18.82%
12/6/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Antalffy
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$182.00+34.12%
12/2/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Carrico
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
12/2/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$145.00 ➝ $153.00+7.60%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$120.00-16.46%
11/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$140.00 ➝ $149.00+6.19%
11/5/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$130.00 ➝ $145.00+11.97%
10/17/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matt O'Brien
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$140.00+5.29%
8/1/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$131.00 ➝ $137.00+16.91%
5/6/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$84.00 ➝ $125.00+17.36%
4/11/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$85.00 ➝ $100.00+0.29%
5/4/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
2/22/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kaczor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:29 AM ET.


GKOS Forecast - Frequently Asked Questions

According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Glaukos is $145.92, with a high forecast of $185.00 and a low forecast of $100.00.

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There is currently 1 sell rating, 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GKOS shares.

According to analysts, Glaukos's stock has a predicted downside of -3.29% based on their 12-month stock forecasts.

Over the previous 90 days, Glaukos's stock had 2 upgrades and 1 downgrade by analysts.

Glaukos has been rated by research analysts at BTIG Research, Citigroup, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Stephens, Stifel Nicolaus, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.

Analysts like Glaukos more than other "medical" companies. The consensus rating score for Glaukos is 2.85 while the average consensus rating score for "medical" companies is 2.81. Learn more on how GKOS compares to other companies.


This page (NYSE:GKOS) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners